Hypoglycemic Activity of Diaglycon in Adrenalin and Alloxan Hyperglycemia
Main Article Content
Abstract
Authors studied the hypoglycemic activity of the drug diaglycon in various models of hyperglycemia. In acute alimentary and alloxan hyperglycemia, diaglycon has a pronounced hypoglycemic effect and is not inferior in activity to the comparison drugs - glukeyr and glipil. It has been established that diaglycon and glucair effectively reduce adrenaline-induced hyperglycemia, while glypil shows little effect. Further, the results showed that diaglycon has a positive effect on the course of zinc-deficient forms of hyperglycemia and in this respect is significantly superior to Glucair.
Article Details
References
Azoulay A., Schneider-Lindner V., Dell’Aniell S. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol. Drug Safety. 2010;19(4):335–42.
Arunachalam G., Samuel S., Marei I., Ding H., Triggle C. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br. J. Pharmacol. 2014;171:523–35.
Abbasi F., Chu J.W., McLaughlin T., Lamendola C., Leary E.T., Reaven G.M. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53(2):159–64.
Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., Wiley C., Selvin E., Wilson R., Bass E.B., Brancati F.L.Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 2007;147(6):386–99.
Brown J.B., Conner C., Nichols G.A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501–6.
Buteau J. GLP-1 signaling and the regulation of pancreatic ß-cells mass/function. Avances en Diabetologi a. 2015;31 (3):3-8. doi: 10.1016/S1134-3230(11)70002-3
Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.
Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.
Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039-1048. doi: 10.1210/en.2011-1499
D'Alessio DA, Vahl TP. Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Curr Diab Rep. 2005;5(5):346-352. doi: 10.1007/s11892-005-0092-2
Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet. Med. 2010;27(7):739–43.
Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014;11(5):306-323.
Scarpello J.H.B. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29:6S36–6S43.
Synergic effects of bitter melon and β-glucan composition on STZ-induced rat diabetes and its complications / J. W. Kim, H. R. Cho, S. B. Moon et al. // J. Microbiol. Biotechnol. – 2012. – Vol. 22, N 1. – P. 147–155.
Evaluation of hypoglycemic activity of total lignans from fructus arctii in the spontaneously diabetic Goto-Kakizaki rats / Z. Xu, J. Ju, K. Wang et al. // J. Ethnopharmacol. – 2014. – Vol. 151, N 1. – P. 548–555.
Effects of arctiin on streptozotocin-induced diabetic retinopathy in SpragueDawley rats / L. C. Lu, W. Zhou, Z. H. Li et al. // Planta. Med. – 2012. – Vol. 78, N 12. – P. 1317–1323.
Effects of Trigonella foenum-graecum (L.) on retinal oxidative stress, and proinflammatory and angiogenic molecular biomarkers in streptozotocin-induced diabetic rats / S. K. Gupta, B. Kumar, T. C. Nag et al. // Mol. Cell. Biochem. – 2014. –Vol. 388, N 2. – P. 1–9.
Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T., Varney J., Johnson J.A. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335(7618):497–507.
Gagnon J., Sheppard E., Anin Y.I. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabet., Obes. Metab. 2012;153(8):3646–356.
Guo X, Yang Q, Dong J, et al. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig. 2016;36(6):433-441. doi: 10.1007/s40261-016-0389-8
He L., Sabet A., Djedjos S., Miller R., Sun X., Hussain M.A., Radovick S., Wondisford F.E. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–46.
Hajiaghaalipour, F. Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus / F. Hajiaghaalipour, M. Khalilpourfarshbafi, A. Arya // Int. J. Biol. Sci. – 2015. – Vol. 11, N 5. – P. 508–524.
Insulin signaling in alpha cells modulates glucagon secretion in vivo / D. Kawamori, A. J. Kurpad, J. Hu et al. // Cell Metabolism. – 2009. – Vol. 9, N 4. – P. 350–361.
Jamila, F. Ethnobotanical survey of medicinal plants used by people in Oriental Morocco to manage various ailments / F. Jamila, E. Mostafa // J. Ethnopharmacol. –2014. – Vol. 154, N 1. – P. 76–87.
Joffe D.J., S. H. Freed. Diabetes in control newsletter. Issue // Diabetes Rew. -2001. v. 76. N 1. –P. 23-24.
Jeppesen J., Zhou M.Y., Chen Y.D., Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093.
Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide inthe treatment of type 2 diabetes: a comprehensive review of the dulaglutide 48. clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776-790. doi: 10.1002/dmrr.2810
Metformin: the gold standart: ascientific handbook / ed. C.J. Bailey, I. W. Campbell, J. Chan et al. –Chichester: John Wiley Sons, Ltd. 2007-P. 288.
Miyazawa, M. Inhibitory compounds of alphaglucosidase activity from Arctium lappa L. / M. Miyazawa, N. Yagi, K. Taguchi // J. Oleo Sci. – 2005. – Vol. 54, N 11. –P. 589–59
Marzouk, M. Hypoglycemic and antioxidative effects of fenugreek and termis seeds powder in streptozotocin-diabetic rats / M. Marzouk, A. M. Soliman, T. Y. Omar // Eur. Rev. Med. Pharmacol. Sci. – 2013. – Vol. 17, N 4. – P. 559–565.
Mechanism of antidiabetic action of compound GII purified from fenugreek
(Trigonella foenum graecum) seeds / D. Puri, K. M. Prabhu, G. Dev et al. // Indian. J. Clin. Biochem. – 2011. – Vol. 26, N 4. – P. 335–346.
Moorthy, R. Anti-hyperglycemic compound (GII) from fenugreek (Trigonella foenum-graecum Linn.) seeds, its purification and effect in diabetes mellitus / R. Moorthy, K. M. Prabhu, P. S. Murthy // Ind. J. Exp. Biol. – 2010. – Vol. 48, N 11. – P. 1111–1118.
Marín-Peñalver J.J., Martín-Timón I., Sevillano-Collantes C., Del Cañizo-Gómez F.J. Update on the treatment of type 2 diabetes mellitus. World J. Diabetes. 2016;7(17):354–95.
Moses R.G. Combination therapy for patients with type 2 diabetes: repaglinide in combination with metformin. Expert Rev. Endocrinol. Metab.2010;5(3):331–42.
Puri, D. Antidiabetic effect of GII compound purified from Fenugreek (Trigonella foenum graecum Linn) seeds in diabetic rabbits / D. Puri, K. M. Prabhu, P. S. Murthy // Indi. J. Clin. Biochem. – 2012. – Vol. 27, N 1. – P. 21–27.
Remizov O.V., Kuraeva T.L. Modeling of diabetes mellitus in experiment // Experimental laboratory. -2003. No. 3. -S. 90-91.
Guidelines for the experimental (preclinical) study of new pharmacological substances / Under. ed. Fisenko V.P. and others - Moscow. 2000. -398 p.
Collection of methods of clinical laboratory research / Ed. Yunuskhodzhaev A.N. -Tashkent. 2000. volume 2. - 703 p.